TABLE 1.
Pairwise method comparisons across four Roche platforms using clinical HCV specimens
| Comparisona | No. of paired testsb | Slope | Intercept | R2 | Mean difference (log10 IU/ml [95% CI]) |
|---|---|---|---|---|---|
| cobas 6800/8800 HCV vs CAP/CTM v2 | 185 | 1.04 | −0.09 | 0.992 | 0.08 (0.06 to 0.11) |
| cobas 6800/8800 HCV vs HPS/CTM v2 | 177 | 0.95 | 0.12 | 0.996 | −0.10 (−0.12 to −0.07) |
| cobas 4800 HCV vs cobas 6800/8800 HCV | 174 | 1.00 | −0.21 | 0.994 | −0.22 (−0.24 to −0.20) |
| cobas 4800 HCV vs CAP/CTM v2 | 170 | 1.05 | −0.33 | 0.988 | −0.14 (−0.17 to −0.10) |
| cobas 4800 HCV vs HPS/CTM v2 | 162 | 0.95 | −0.10 | 0.992 | −0.31 (−0.34 to −0.28) |
| HPS/CTM v2 vs CAP/CTM v2 | 172 | 1.11 | −0.31 | 0.991 | 0.17 (0.13 to 0.21) |
a
CAP/CTM v2, Cobas AmpliPrep/Cobas TaqMan HCV quantitative test, version 2; HCV, hepatitis C virus; HPS/CTM v2, Cobas TaqMan HCV test, version 2 for use with the High Pure system.
b
Only valid paired results within the respective common linear ranges were included in the calculations.